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We have examined whether alterations in the growth 
hormone/insulin- like growth factor- 1 axis play a role in 
the pathogenesis of psoriasis . Serum, urine, full skin 
biopsies, and suction blister roofs were obtained from 
patients with psoriasis and from healthy controls. Serum 
concentrations ofinsulin- like growth factor-1 and insulin-
like growth factor binding protein- 3 were measured by 
radioitnmunoassay. Growth hormone-binding protein 
was measured by ligand-mediated immunofunctional 
assay. Growth hormone conce1;1tration in urine was 
measured by an immunometric assay, and growth 
hormone receptor-gene expression was measured by 
RNase protection assay or by quantitative reverse tran-
scriptase polymerase chain reaction in total RNA isolated 
frotn epidermal suction blister roofs. Serum concentra-
tions of insulin-like growth factor- 1 (249 ± 12 J..lg per 
liter, mean ± SEM, n = 42, artd 277 ± 21 J..lg per liter, 
n = 9, for psoriatic patients and controls, respectively), 
insulin-like growth factor binding protein-3 
(3.1 ± 0.08 mg per liter, n = 42, and 3.3 ± 0.22 mg per 
A mong the factors that have been suggested to play a role in the pathogenesis of psoriasis, growth honnone and insulin-like growth fac tor-1 (IGF-1) are two candidates. Increased growth hormone levels were demonstrated in 70 psoriatic patients by Weber et a/ over a decade ago 
(Weber et al, 1981), and in several open studies the use of the growth 
hormone secretion inhibitor, somatostatin , has led to clearance of the 
skin lesions in psoriatic patients (Weber et a/, 1982; Venier et al, 1988). 
Case reports of worsening of psori asis in a growth hormone-defi cient 
girl, stLictly correlated to growth hormone therapy cycles (M aghnie 
et al, 1990), and clearing of ps01i asis after renwval of a grow th 
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liter, n = 9), growth hormone- binding protein 
(344 ± 65 pmol per liter, n = 10, and 311 ± 83 pmol 
per li~er, n = 9), urinary growth hormone excretion 
during 24 h (12.8 ± 2. 7 J..llU per 24 h, n = 12, and 
12.3 ± 1.6 J..l.IU per 24 h, n = 9), and epidermal growth 
hormone receptor gene expression [32 ± 12 X 103 mRNA 
transcripts per J..lg total RNA (involved skin), n ::::: 11, and 
47 ± 14 X 103 mRNA transcripts per J..lg total RNA, n = 
9] were similar in patients and controls. For insulin-like 
growth factor-1 and insulin- like growth factor binding 
protein-3 the values in psoriatic patients were alSo similar 
to those in larger control groups, n = 195 and n = 400, 
respectively. In addition, we found no evidence of locitl 
expression of growth hormone or prolactin in full skin 
punch biopsies from psoriatic involved skin by reverse 
transcriptase polymerase chain reaction. In conclusion, 
our results suggest that alterations in the growth hormone/ 
insulin-like growth factor- 1 axis do not play a major role 
in the pathogenesis of psoriasis. Key words: bindittg proteitts! 
lwma11 growth horn1one receptor. ] Invest Dermatol 109:661-
665, 1997 
hormone-producing pituitary adenoma in a patient with acromegaly 
(Todd et a/, 1991), give further support for a role of growth hormone in 
psoriasis. This has been challenged, however, because other investigators 
have been unable to demonsu·ate elevated serum growth hormone 
levels in psoriatic patients (Mackie et a/, 1983; Priestley et a/, 1984). 
There have also been reports of inconclusive results when treating 
psoriasis with somatostatin (Guilhou et a/, 19S2). Concerning IGF-1, 
the major mediator of growth hormone, it has been shown that the 
IGF-1 receptor is overexpressed in ps01iatic involved skin (Krane eta/, 
1992), and that keratinocytes fi:om nonlesional psoriatic skin have an 
increased response to IGF-1 (Ristow, 1993). 
In serum , the maj01ity of IGF-1 is bound to IGF-binding protein-
3 (IGFBP3). It is believed that IGFBP3 prolongs the half-life of 
IGF-1 in serum and at a cellular level modulates the access of IGF to 
their receptors (Cohick and Clemm.ons, 1993) . 
The abili ty of the skin to respond to growth honnone directly 
requires e>..lJression of functional growth hormone receptors (GHR) . 
It has previously been demonstrated that GHR are expressed in human 
skin (Oakes eta/, 1992; Tavakkol et al, 1992); however, it has not been 
convincingly shown that the full-length GHR is expressed in the 
epidemtis. 
The objectives of tlus study were to investiga te if nom1al human 
epidermis expresses . GHR and to test the hypothesis that the growth 
hormone/ I G F-1 axis is involved in the pathogenesis of psoriasis. 
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MATERIALS AND METHODS 
Subjects Pati ents with mild or moderate psoriasis with no ongoing treatment 
for their psoriasis were selected from the out-patient clinic of the Department 
of Dermatology, Sahlgrenska University Hospital, Gi:iteborg or fro m the Swedish 
Psoriasis Geneti c Proj ect (Swanbeck et al, 1994) . The control group consisted 
of personnel working in our laboratory. When possible, the results were also 
compared wi th verif1 ed reference values for each assay. In one group of 12 
psoriati c patients (Pso riatic 1), GI-IR gene expression was studied in suction 
blister roofs, IGF-1, IGFBP3, and growth hormone-binding protein (G HBP) 
were n1easured in serun1, and growth horntone excretjon was n1easured in 
urine coll ected over a 24-h period. In an additiona.l group of 30 pati ents with 
psorias is (Psoriatic II), IGF-1 and IGFBP3 were measured. Patients and controls 
gave thei r informed consent to the procedure, and the study was approved by 
the ethics committee of the Medical Faculty, University of Gi:iteborg. None of 
the subj ects were taking medication and none of them were pregnant. T he age 
of the control group ranged from 24 to 56 y, with a mean age of 40.6 
(n = 9). T he age of the patients in the psori atic 1 and ll groups ranged fi·om 
33 to 44 y (mean 39.5, n = 12) and from 27 to 49 y (mean 39.0, n = 30), 
respecrively. T he values obtained for IGF-1 in the psoriati c l and [[ groups 
were also compared with those in a ra ndomized control group, n = 195, from 
the Monica study (Landin-Wilh elmsen eta/, 1994), and the values for IGFBP3 
were compared with those in a randomized control group consisting of 400 
persons (Wilhelmsen and Landin-Wilhelmsen, personal communica tion). 
Skin samples Suction blisters were produced by application of a negati ve 
pressure of 200 mM Hg to the skin for 2 h as has been previously described 
(Kiistala and Mustakallio, 1967). Full skin punch biopsies and biopsies from 
dennis under the epidermal blister roofs were taken under local anaesthesia (1% 
lidocain without adrenaline). Skin samples were taken from lesiona l skin in the 
Psoriatic l group and from a corresponding area in th e control group. The 
tissue samples were immediately frozen in liquid nitrogen and sto red at -70°C 
until analyzed. 
RNA isolation Total RNA was prepared fro m tissues using RNeasy Total 
rtNA Kit (Qiagen, Hilden, Gennany), or Microscale Total R NA Separating 
Kit (Ciontech, Palo Alto , CA) . 
RNase protection assay (RPA) GH.R gene expression was analyzed by an 
RPA, using the R ibonuclease Protection Assay Kit (Ambion, Austin , TX). 
Samples consisted of 40 ~g total RNA isolated fiom suction blister roofs of 
normal epidennis, or from punch biopsies of normal skin . Seven micrograms 
of total RNA isolated from liver was included as a positive control. A 35S-
labeled growth hom10ne-receptor anti-sense RNA probe was generated by 
i11 11itro transcription usipg Sp6 polymerase (Promega, Madison, Wl) fi·om an 
EcoR1 (Promega) linearized PGEM-7Z (+) plasmid carrying a 500-bp insert 
co rresponding to exon 10 of the human GHR gene (N ilsson eta/, 1995) . The 
samples were hybridized with the probe overnight at 45°C. l~ase digestion 
was carried out at 37°C for 30 min. Negative controls consisted of samples 
lacking RNA or containing yeast tRNA only. Protected fi·agments were 
separated on a 6% actylamide gel an d the radioactivity was detected on a 
phosphor image screen (Phosphorlmager, Molecular Dynamics , Sunnyvale, CA). 
Measuretnent of growth hortnone and prolactin gene expression by 
reverse transcriptase polymerase chain reaction (RT-PCR) One micro-
gram RNA, isolated from punch biopsies of psoriatic lesional skin , was used as 
a template for first strand complemen.ta1y DNA (eDNA) synthesis. T he eDNA 
synthesis was ca rri ed out for 50 min at 42°C in reverse transctiptase buffer 
[50 mM KCL, 50 mM Tris-HCl (pH 8.3), 10 mM MgC12, 10 mM dithiothreitol, 
and 0.5 mM Spermidine], 1 ~g random primer (Promega), 25 U AMY reverse 
transcriptase (Promega), 20 U Rnasin (Promega), and dNTPs at a final 
concentration of 1.5 mM per nucleotide, in a total volume of 20 111. The 
reaction was terminated at 70°C for 5 i11in. The polymerase chain reactioi1 
(PCR) was canied out in PCR buffer [50 mM KCl, 10 mM Tris H C I (pH 
8.3), 1.5 mM M gCI2, 0.001% (wt/vol) gel <~ tin (Perkin-EL11er/Ce tus, N orwalk, 
CT)] with 2.5 U Tag DNA polymerase (Prom ega), 50 pmol of primers, and 5 
J..Ll of the reverse transcriptase reaction using hot start (94°C, 4 min) , followed 
by 40 cycles of 15-s denaturation at 94°C, 15-s annealing at 58°C or 66°C for 
growth hormone and prolactin, respectively, and 30-s elongation at 72°C. Total 
RNA isolated fico m human pituitary tissue was used as a positive contro l. In 
order to test the quality of the RNA and the eDNA, the IGF receptor was 
amplified by RT-PCR as described above (annealing at 58°C, 30 cycles). After 
amplification, samples were electrophoresed through an agarose gel (2% wt/ 
vol) and visualized by UV light. 
Measurement of GHR gene expression by quantitative RT-PCR RT-
l>CR was performed as described before (Hermansson et a/, 1997). Briefl y, total 
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RNA, isolated from suction blister roo£1 of nom1al or psoriati c epidermis, or 
syntheti c l~A. identical to wild-type C HI\. mRNA (GHR STD) , was reversed 
transcribed to eDNA together with a fixed amount of an internal RNA standard 
(GHR MUT), differing from the wild- type GHR mRNA by one nucleotide. 
The eDNA was amplified by PC R using one biotinylated primer. An aliquot 
of tbe PCR. reaction was bound to strcptavidin-coated micro titer plates and 
the :uuount o f th e two transcripts wa~ n1easured in two separate nUnisequencing 
reactions usi ng radio labeled n.ucleo tides corresponding to each of the transcripts. 
The GHR ml~A levels were calculated by comparing the ratio of the rwo 
trancripts in tissue samples with the standard curve constructed from GHR STD. 
Verification of the suction blister method by RT-PCR of hepatocyte 
growth factor (HGF) To ensure that there was no fibroblast contamination 
in the suction blister roofs, total RNA was iso lated as desc1ibed above and 
HGF was amplified. RT- PCR was ca rri ed out as described above (annealing at 
60°C, 30 cycles). Total RNA isolated ficom li ver, and dermal and full skin 
punch biopsies of normal skin, were used as positive controls. In order to test 
the quality of the RNA and eDNA, the IGF-receptor was amplified by RT-
PCR, as described above. 
PCR primers Primers used in the RT-PCR assays were: growth hormone 
(5' -CCAACCATTCCCTTATCC and 5' -CAGGAATGTCTCGACCTT 
nucleotides 4--21 and 531-514, respectively, Denoto el a/, 1981) , prolactin (5 ' -
GT CCTGTCCCACTACATCCA and 5' -GCCCACATCCATTTCATCTA 
nucleo tides 158-177 and 708-689, respecti vely, Cooke eta/, 1981), GHR (5'-
Biotin-CTGGAC AGATGAGGTTCA and 5' -GTG CTTCCCATCTCACTT 
nucleo tides 201-218 and 532-515, respectively, Leung ct ttl, 1987), !GF-
receptor (5'-AACCACGAGGCTGAGAAGCT and 5'-CAGCATAAT-
CACCAACCCTC nucleotides 2463-2482 and 2908- 2889, respectively, Ullrich 
et a/, 1986) , and HGF (5'-ATGGAAGACTTACACCGTCA and 5'-
TGCCACTCGTAATAGACAT nucleotides 1257-1277 and 1899-1879, 
respectively, Nakamura et a/, 1989). 
Itnmunoassays Growth hormone concentration in 24-h total urine was 
measured using an inununometric assay for urinary growth hormone (.Bio-
Meri eux , Lyon, France). The method has a detection limit of 1.3 ~U per liter 
and the coeffi cient of variation was less than 8% in the concentration range 
measured in the study. T he IGF-1 concentrations were measured in acid-
etll~nol extracted serum using an RlA kit (Nichols lustitute, SanJuan Capistrano , 
CA). T he coefficient of va riation, in the concentration .range measured in the 
study, was Jess than 6%. I G FBP3 concentrations in serum were determined 
using an RIA kit (Nichols Institute) . T he coefficient of variation was less than 
5% in the concentration range measured in the study. GHBP was measured by 
li gand- mediated inm1unofunctional assay as has been previously described 
(Carlsson eta/, 1991). T he assay had an in tra-assay coefficient of variation of7%. 
Statistical methods Student's t test (Statisti ca for Windows 4.5, St<lt Soft , 
T ulsa, OK) was used to compare patients with controls. 
RESULTS 
Growth hormone/IGF- 1 axis in psoriatic patients Total urinary 
excretion of growth h o rmone (UGH) and serum levels of IGF-1 and 
IGFBP3 were not signifi cantly different in the p soriati c group compared 
with hea lthy controls (Table 1). Wh en valu es for IGF-1 and UGH 
were plo tted against age and compared with larger control groups 
(Monica study, Landin-Wilhelmsen et a/, 1994; and an in-house 
referen ce population, respectively) , no difference between th e gro ups 
could be d er11onstrated (Fig la, b). Similar results were obtained for 
IGFBP3 (da ta not shown). 
Growth hormone/IGF axis in human skin 
Specificity of the suction blister ll'l etltod In order to study if the su ction blisters 
were contaminated with dermal fibroblasts, HGF gene expression was 
measured by RT-PCR on total RNA isolated from the epidermal 
bliste r roofs. HGF transetipts were not found in the epidermal skin 
bliste rs but were d etected in dermal and full skin punch biopsies, 
inclicating a good separation b etween the epidermis and the dennis 
(Fig 2) . 
Expressior1 of the GHR gene An RPA was used to m easure GHR 
expression in blister roofs and full skin of nom1al volunteers. A 
protected fragm.ent with the expected le ngth (500 bp) was obtained 
w hen total RNA fi·om full skin , epidermis, and liver (positive control) 
was hybridized with the GHR probe (Fig 3), d emonstrating that the 
GHR is expressed in these tissues. 
GHR gene expression was measured by quantitative RT-PCR in 
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Table I. IGF-1, IGFBP3, and UGH in psoriatic patients and h ealthy con trols" 
Control (n = 9) 
Psoriatic I (n = 12) 
Psoriatic II (n = 30) 
Psoriatic I + II (n = 42) 
IGF- 1 (f.l.g per li t~r) 
277::!:: 21 
259 ::!:: 22 
246 :t 15 
249 :t 12 
IGFBP3 (mg per li ter) 
3.3 ::!:: 0.22 
3.2 :t 0.13 
3.1 :t 0. 10 
3.1 ::!:: 0.08 
UGH (~LI U per 24 h) 
12.3::!:: 1.6 
12.8 :t 2.7 
"Valu es nrc mean ~ SEM. Student's t test was per[onn c.d for each v:trinble b~twce n each b'Toup , no difl"ercnces bct\veen the va lues were signific:t nt. 
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Figure 1. No difference in age-related serum levels of IGF-1, or in 
urinary growth hormone excretion between the psoriatic group and 
healthy controls. (a) Age-related serum levels of IGF-1 in control subjects 
(e ), ps01iatic I patients(. ). and psoriatic II patients (0 ). ---- indicates mean 
values and - indicates 95% confidence interva l for a larger contro l group 
(Landin-Wilhelmsen el nf, 1994) . (b) Age-related UGH in control subjects (e ) 
and psoriatic I patients (. ). - indicates 95% confidence interval for an i.n -
house reference population. 
total RNA isolated ti-o m suction b lister roofs from in volved sk in of 11 
psoriatic patients and of I'tine control subj ects . In two patients, G HR. 
gene express io n was undetectable in our assay. N o significant differen ce 
be tween th e two groups was fou nd (Fig 4a) . Furthermore, there was 
no signi ficant difference in the serum GHBP levels between the two 
groups (Fig 4b). 
C 1vwth hor111o11e a11d pmlactin gene expressio11 To test the hypothesis that 
local expression of the growth hormone gene o r the pro lacti n gene is 
involved in the pathogenesis of psoi-ias is, R.T- PCR was used in an 
attempt to amplifY growth hormone m.RNA or pro lactin n~NA in 
w hole skin punch biopsies Ei.·om invo lved skin of eight psoriatic patients. 
No growth horm one o r prolactin transcripts were detected in any of 
HGF+ 603 bp 
310 bp 
Figure 2. No detection ofHGF gene expression by RT-PCR snggesting 
no fibroblast contatnination in the epidennal blister roofs. Messenger 
I<..NA transc ripts of HGF amplified by I<..T-PCR from total I<..NA isolated fi·om 
epidermal blister roofs. Lane 1, full skin biopsy of normal skin ; la11e 2, dermal 
biopsy of nonnal skin; /nn e 3, liver; fnues 4-15, epidermal blister rooE; fn11 e 16, 
e :1 74/ HAElll DNA marker. The same expetiment was repea ted with all 
bl.isters with similar results. 
2 3 4 5 6 7 
603 bp-
+GHR 
310 bp-
Figure 3. The GHR gene is expressed in human epidermis. GHR gene 
expression, in epidermal bliste r roo& of normal skin and in fi.Ill skin biopsies of 
normal skin , demonstrated by RPA. Ulllc 1, e 174/ HAEllt DNA marker; fa11e 
2, GHR probe hyb1idized with no mRNA; fn11c 3, GHR probe not subjected 
to RNases; laue 4, yeast mRNA ; fm1c 5, epidennis 40 pg; fm~e 6, full skin 
biopsy 40 pg; laue 7, li ver 7 pg. 
the skin samples tested (data not shown). The quality of the RNA and 
the eDNA was confi rm ed by detection of IG F-1 receptor transcripts 
in the same samples. Total RNA from human pituitati es (obtained at 
surgery) was used as a positive control for both growth h ormone and 
prolactin, to demonstrate that th e R.T-PCR could detec t growth 
hormone and prolactin m.RNA . 
DISCUSS ION 
T he question of w hether the growth hormone / IGF-1 axis plays a 
functional ro.le in the pathogenesis of psoriasis is controversial (Weber 
et nl, 1 981; Priestley et nl, 1984; Krane e/ a/, 1992). In this study, 
urina1y growth hormone excretion, serum levels of IGF-1, IGFBP3, 
and GHBP, and GHR gene express ion in the skin were m easured in 
a gro up of patients with psoriasis and in normal contro ls. We found 
no signifi cant differences between the groups and we were unable to 
provide evidence of a ro le of growth hormo ne and lG.F-1 in psoriasis. 
T he suction b lister m ethod (Kiista la and Mustakallio, 1967) was 
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Figure 4. Expression levels of GHR, and serum levels of GHBP in 
psoriatic patients and healthy controls. (11) Expression levels + SEM of 
G HR. in sucti o n bli ster roofs of nine control subj ects and in in volved skin of 
11 pati ents with pso ri as is (Psoriati c 1). (/J) Sermn levels + SEM of G HI3P in 
nine control subj ects and ·12 psoriatic patients (Pso ri atic 1). 
used to obtain epidermal tissue free of derm al contamin ation. Previo us 
evaluati on of the method has demonstrated physical separation between 
th e basal membrane and the basa l kerati.n ocytes (Kiistala and Mustakalu o, 
1967). Using mo rph ologi c examination, we could not ru le out minor 
contam ination by dermal fibroblasts; however, possible contamination 
ca n be ve ri fi ed or exd uded if mRNA restricted to either epiden11.is or 
dermis are identifi ed. Por that purpose, expression of H G F, which is 
restricted to dermal fibroblasts (Gohda et a/, 1994) and endothelial ceLls 
(Grant ct a/, 1993), was studi ed in sucti on blister roofs and compared 
with dermal and fuLl skin bi opsies. We were un able to detect HGF-
gene express io n in total RNA isolated from the blister roofs, suggesti ng 
that there was no contaminati on by dermal fibroblasts. Our results 
demo nstrate that suction blister roofs and pun ch biopsies of the 
underl ying derm al skin can be used fo r eva luatio n of gene expressio n 
in different compa rtm ents of the skin , and fu rtherm ore o ur data show 
that both no1·maJ epidermis and pso ri atic involved epidermis express 
the GHR gent: . 
A previous study has demonstrated immunohistochemical sta ining 
fo r GHR in al l epidermal layers except the stratum corneum , in dermal 
swt:a t glands and sebaceous glands, and in derm al fibroblasts (Oa kes 
et a/, 1. 992); however, the study does not provide conclusive evidence 
o f th e exp ression ofG HR in human epidermis beca use th e monoclonal 
anti body used (MAB 263) is directed against th e extra el lu lar part of 
the G HR and is therefo re unable to distinguish between GI-IBP and 
th e membrane-bound G HR. Tava kko l et a/ (1992) measured GHR 
expression in cul tured dermal fibrob lasts, melanocytes, and kerabnocytes 
and by semjquantitative RT-PC R demonstrated low levels of Gl-ll"t 
mRNA in keratome bi opsies . Keratome bi opsies can, however, be 
co ntanunated by dermal fibroblasts or lack some of th e basal epi denna l 
layer cells and therefore give fa lse positive or false negative results. 
O m study demonstrates that G HR is expressed in hum an epidennjs 
free of co ntaminatin g fibroblasts. GH l"t mRNA levels in th e sucti on 
bl isters were low compa red with levels previously reported in other 
human tissues such as th e liver and adipose tissue (Herma nsson et a/, 
T H E JOURNAL 0 1' INVESTIGATIVE DEI'lMATOLOGY 
1997). W e can the refore no t rule out the possibili ty that tht: G HR_ 
exp ress ion is restricted to the melanocyte cell populatio n, as sugges ted 
by Tavakkol et a/. Wh en G l-lR expression levt:ls were quantified we 
fo und no di8:erence betvveen the contro l group and the psoriati c 
pati ents. Furthermore, there were no signjficant differences in serum 
levels of G H.BP. 
We fo und no evidence of local expression of growth horm one or 
prolactin in the psoriatic lesions. T ht: latter results are of special 
signi fican ce because psoriasis is characterized by infiltrating mo nocytes, 
lymphocytes, and neutrophi l granulocytes, and lymph ocytes may 
express growth honnone (1-lattOLi el a/, '1990) and prolac tin (D imattia 
et a/, 1988). 
T he n1.easurement of growth hormone excretion in urine is an 
analys is that to some extent represents the integrated growth ho rmo ne 
excretio n over 24 h (G irard ct a/, 1987; Girard and Fischer-Wasels, 
1990). There have been repo rts of elevated (Weber e£ a/, 1981) as wel.l 
as no rmal (M ackie et a/, 1983; Priestley el a/, 1984) serum growth 
hormo ne leve ls in psoriatic patients. Our results did not show any 
dj£ferences between th e ps01iatic patients and the control group, and 
th is was also true w hen comparin g the UGH levels in psot;ati c patients 
with in- ho use reference va lu es for th e assay. 
!GF-1 has been sugges ted to play a ro le in th e pathogenesis of 
pso1iasis (Tl...istow, 1993; Kran e e£ a/, 1992); however, serum levels of 
IGP-1 in patients with psoriasis have previously been reported to be 
the sa me as in nonnals (Nickoloff ef a/, 1987), and this was confirmed 
in our stud y. In serum , the majority of IGF-1 is boun d to 
IGFBP3 (Collick and C lemmons, 1993) . Increased bioactivity of 
LGF-1 by IGFBP3 was demonstrated in a study w here systemi cally 
adminjstered IGF-1 complexed with IG FBP3 had greater effects on 
wound healin g compared w ith equivalent amo unts of lGF-1 alo ne 
(H amon et a/, 1993). The mechanjsms behind the enhanced effect of 
IGF-1 w hen coadmi 1ustered with IGFBP are unkn own but it may be 
du e to targeting th e IGF-l to its receptor or preventing downregulation 
of receptors . W e investigated w hether pso riati c patients had changed 
IGFBP3 levels because an altered regulati on of IGFB P3 could then 
explain the in creased response to IGF-1 by keratinocytes from psoriatic 
patients (Ristow, ] 993) , and it could also be responsible for the 
overexpression oftbe JGF- l receptor seen in psOLiatic epidermis (Krane 
et al, 1992). We foun d no signifi cant difference between the psoriatic 
and the contro l gro up, however, and this w as also tru e w hen comparing 
the lGFBP3 levels in psoriatic patients with those in a larger randomized 
control group. Therefore, our resul ts do not support an altered 
regula tion of circulating IGFBP3 in psoriasis; however, we cann ot rule 
out a loca l a.l ternion, w hi ch is suggested by th e recent fmding that in 
interstitia l fluid taken fi·om .in volved psoriati c les io ns the intact do ublet 
IGFBP3 concentration was raised , compared with uninvolved sk.in 
(Xu el a/, 1996). 
In conclusion, our data show that no m1 aJ epidetmis and psoriatic 
in volved epidermis express GHR; however, o ur findin gs do not 
support a maj or role of growth hom1o ne and / or I G F-1 in the 
pathogenesis of psori asis. 
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Jo llll rlat ioll (S tockholm, S lllcdcll), Giiteb01gs Uikaresii/lskap , t1 11d the S111cdisft Medical 
Rcscmrh Cotmcil ('/'1 285, 11 502) . The a11thors mr gmtif11/ to Gette/1/ cch (Sa 11 Fm11cisco, 
CA) for ki,dly pmviding the rca,Qents fo r GH BP nteaslltrn"'l'lls, and to Drs A nders 
N ilsson, S t!Cn Enerbiick, ai/CI Cines 0 /tfsson .for j)lllllidin,~ the GHR. •vceptor pmbe. 
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